WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Now Available: The U.S. Dredge Report 2025 — download today for expert dredging market insights and data → Click Here

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

330.94 +12.09 (+3.79%)
Streaming Delayed Price Updated: 9:35 AM EDT, Apr 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
News headline image
51 Biggest Movers From Yesterday ↗
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Microbot Medical (NASDAQ:MBOT) stock moved upwards by 47.87% to $8.02 during Monday's regular session. The current volume of 63.6 million shares is 153229.83%... 
Via Benzinga
News headline image
34 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares jumped 69.6% to $9.19 after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY... 
Via Benzinga
News headline image
BridgeBio Pharma Stock Crashes As Pfizer-Rivaling Heart Drug Flops ↗
Patients who received the drug didn't improve in the six-minute walking test. 
Via Investor's Business Daily
News headline image
FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol ↗
The FDA has approved Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) Leqvio (inclisiran) to lower low-density lipoprotein cholesterol (LDL-C). Leqvio is... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug... 
Via Benzinga
News headline image
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients... 
Via Benzinga
News headline image
Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022 ↗
Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its ... 
Via Benzinga
News headline image
Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
News headline image
Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentations at Upcoming Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Read Why Analysts Are Going Bullish On This Large-Cap Pharma Stock ↗
RBC Capital has upgraded Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) to Outperform from Sector Perform with a price target of $225, up from $144. While M... 
Via Benzinga
News headline image
How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022 ↗
Alnylam is working on a drug that could tackle transthyretin cardiomyopathy. 
Via Investor's Business Daily
News headline image
Expert Ratings For Alnylam Pharmaceuticals ↗
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021 ↗
Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE: 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A... 
Via Benzinga
News headline image
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? ↗
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... 
Via Benzinga
News headline image
Dicerna Stock Rockets On Novo Nordisk's $3.3 Billion Takeover Plan ↗
Novo Nordisk is buying an RNA interference company. 
Via Investor's Business Daily
News headline image
Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Virtual R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Named a Science Magazine Top Employer for Third Consecutive Year
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.